CareDx, Inc. (NASDAQ:CDNA – Get Free Report) has received a consensus rating of “Hold” from the seven research firms that are presently covering the company, MarketBeat reports. One research analyst has rated the stock with a sell rating, three have issued a hold rating, two have issued a buy rating and one has assigned a strong buy rating to the company. The average 12-month price objective among analysts that have issued ratings on the stock in the last year is $47.75.
A number of analysts have issued reports on the stock. Weiss Ratings upgraded shares of CareDx from a “sell (d)” rating to a “sell (d+)” rating in a research note on Thursday, July 30th. Wall Street Zen upgraded shares of CareDx from a “buy” rating to a “strong-buy” rating in a research note on Sunday, May 3rd. HC Wainwright restated a “neutral” rating and set a $46.00 price target on shares of CareDx in a report on Friday, July 31st. Craig Hallum raised shares of CareDx from a “hold” rating to a “buy” rating and set a $64.00 price objective for the company in a research note on Monday, August 3rd. Finally, Zacks Research raised shares of CareDx from a “hold” rating to a “strong-buy” rating in a research note on Thursday, August 6th.
Check Out Our Latest Stock Analysis on CareDx
CareDx Price Performance
CareDx (NASDAQ:CDNA – Get Free Report) last posted its quarterly earnings results on Thursday, July 30th. The company reported $0.37 earnings per share for the quarter, topping analysts’ consensus estimates of $0.23 by $0.14. The company had revenue of $131.95 million during the quarter, compared to the consensus estimate of $114.05 million. CareDx had a return on equity of 2.87% and a net margin of 24.23%.The business’s quarterly revenue was up 52.2% on a year-over-year basis. During the same period last year, the business earned ($0.16) EPS. On average, equities analysts anticipate that CareDx will post 0.47 EPS for the current year.
Insider Buying and Selling
In other news, Director Christine Cournoyer sold 16,000 shares of the company’s stock in a transaction dated Tuesday, August 4th. The stock was sold at an average price of $46.94, for a total transaction of $751,040.00. Following the completion of the sale, the director owned 42,943 shares in the company, valued at approximately $2,015,744.42. This represents a 27.14% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO John Walter Hanna, Jr. sold 39,900 shares of the stock in a transaction dated Monday, June 29th. The shares were sold at an average price of $29.24, for a total value of $1,166,676.00. Following the transaction, the chief executive officer directly owned 661,959 shares in the company, valued at approximately $19,355,681.16. This represents a 5.68% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 114,936 shares of company stock valued at $3,770,348 in the last three months. 2.40% of the stock is currently owned by corporate insiders.
Institutional Investors Weigh In On CareDx
Large investors have recently added to or reduced their stakes in the stock. Goldman Sachs Group Inc. raised its position in shares of CareDx by 18.1% in the first quarter. Goldman Sachs Group Inc. now owns 1,110,014 shares of the company’s stock valued at $19,703,000 after purchasing an additional 170,504 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its stake in CareDx by 11.3% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 133,966 shares of the company’s stock valued at $2,378,000 after buying an additional 13,619 shares during the last quarter. JPMorgan Chase & Co. grew its stake in CareDx by 41.2% in the 2nd quarter. JPMorgan Chase & Co. now owns 68,602 shares of the company’s stock valued at $1,340,000 after buying an additional 20,028 shares during the last quarter. First Trust Advisors LP acquired a new position in CareDx in the 2nd quarter valued at $1,822,000. Finally, Nebula Research & Development LLC bought a new position in CareDx in the 2nd quarter worth $281,000.
About CareDx
CareDx, Inc (NASDAQ: CDNA) is a precision diagnostics company focused on the care of transplant patients. The firm develops and commercializes non‐invasive tests designed to detect organ transplant rejection and infection risk, helping physicians make informed management decisions throughout the post‐transplant journey.
The company’s core product portfolio includes AlloMap®, a gene expression profiling test for heart transplant recipients, and AlloSure®, a donor‐derived cell‐free DNA assay used primarily in kidney transplant monitoring.
Featured Stories
- Five stocks we like better than CareDx
- SoundHound AI Sends a Loud Signal After Its Q2 Earnings Beat
- 3 Dividend Champion Utilities for a Market That Can’t Sit Still
- These 3 Most-Upgraded Stocks Have Almost Nothing to Do With AI
- First Solar’s Profit Engine Faces a New Policy Test in Washington
Receive News & Ratings for CareDx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CareDx and related companies with MarketBeat.com's FREE daily email newsletter.
